Cyplexinol: A Natural BMP Complex with Osteoinductive and Anti- Inflammatory Activity Promotes De Novo Bone and Joint Tissue Growth

Abstract

Sustaining the health of the bones and joints is a pertinent issue that is challenging for the medical community nationwide. Chronic inflammation has been implicated as a major contributing factor for the systemic degradation and disruption of the articular and skeletal systems. Accordingly, medical practitioners and pharmaceutical companies are currently directing treatments toward restoring healthy inflammatory response in order to strengthen the human body’s capability to target endogenous degradation of bone and joint tissue. However, improving overall health involves more than targeting inflammation, and should also focus on activating cellular machinery which supports the regeneration of de novo bone and cartilage through a process known as osteoinduction. Bone Morphogenetic Proteins (BMPs) have been identified as the regulators of the osteogenic differentiation of Mesenchymal Stem Cells (MSCs) into multiple cell lineages such as osteoblasts and chondrocytes. Cyplexinol® is a natural BMP complex, which consists of a collagen fragment matrix with the BMPs and endogenous growth factors bound within and to the matrix. Upon oral administration of the BMP-complex, the BMP moieties bind to receptors within the GI lumen where they quickly confer both osteoinductive and anti-inflammatory activity. It is the osteogenic properties of the BMPs which differentiate the MSCs into osteoblasts to promote the growth of de novo bone tissue, providing the critical surface for minerals to bind to healthy bones. Similarly, the osteoinductive proteins have also been proven to turn MSCs into chondrocytes for new cartilage tissue growth via proteoglycan excretion. This review will describe clinical work which demonstrates the efficacy of Cyplexinol®, highlighting how this supplement induces MSC differentiation.